Home/Indications/Immunology/Psoriatic Arthritis

Psoriatic Arthritis

Immunology 9 original drugs

Novel Drugs

Reformulations

Drug Targets

Immunology indication. Psoriatic Arthritis has 9 FDA-approved novel treatments, led by Johnson & Johnson, with 50 active industry clinical trials across 14 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Psoriatic Arthritis Market Leaders

Companies with the most FDA-approved novel Psoriatic Arthritis drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

Adalimumab

AbbVie

Estimated · fresh NCT06100744

Q1 2027

bimekizumab

UCB Biopharma SRL

Estimated · fresh NCT06506916

Q2 2027

Zasocitinib

Takeda

Estimated · fresh NCT06671483

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Psoriatic Arthritis Treatments by Mechanism

Top 11 mechanisms across 34 industry trials with a known mechanism of action.

See full pipeline →

Tyrosine Kinase 2 Inhibitor

3 trials 3 active 1 sponsor

Interleukin-17A Antagonist

14 trials 2 active 2 sponsors

Phosphodiesterase 4 Inhibitor

5 trials 2 active 1 sponsor

TNF

3 trials 1 active 1 sponsor

Glucose-dependent Insulinotropic Polypeptide Receptor Agonist

1 trials 1 active 1 sponsor

Tumor Necrosis Factor Blocker

3 trials 2 sponsors

Janus Kinase Inhibitor

1 trials 1 sponsor

Selective T Cell Costimulation Modulator

1 trials 1 sponsor

Interleukin-23 Antagonist

1 trials 1 sponsor

Interleukin-12 Antagonist

1 trials 1 sponsor

Folate Analog Metabolic Inhibitor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Psoriatic Arthritis Clinical Pipeline by Phase

120 industry-sponsored trials across 37 sponsors

View full landscape →

Showing 9 of 9 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	RECRUITING	2027-11	NCT06864026
CARE ARTHRITIS LTD.	Upadacitinib 15 MG [Rinvoq]	—	RECRUITING	2028-09	NCT06454188
Eli Lilly	Ixekizumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2024-08-08	NCT05855967
Amgen	Apremilast	Phosphodiesterase 4 Inhibitor [EPC]	COMPLETED	2021-10-26	NCT03783026
AbbVie	methotrexate (MTX)	—	COMPLETED	2019-09-23	NCT02814175
Novartis	Secukinumab 300 mg	—	COMPLETED	2018-12-05	NCT02798211
Eli Lilly	Ixekizumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2018-11-15	NCT03151551
Kyowa Kirin Co., Ltd.	Brodalumab 210mg SC	—	COMPLETED	2017-01-10	NCT04183881
Pfizer	—	—	COMPLETED	2011-07	NCT01147874

Showing 67 of 67 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
AbbVie	Adalimumab	TNF	RECRUITING	2026-09	NCT06100744
Takeda	Zasocitinib	—	RECRUITING	2027-05-18	NCT06671483
Takeda	Zasocitinib	—	RECRUITING	2027-05-18	NCT06671496
Amgen	Apremilast	Phosphodiesterase 4 Inhibitor [EPC]	RECRUITING	2028-03-21	NCT04804553
UCB Biopharma SRL	Bimekizumab	—	RECRUITING	2028-04-12	NCT06668181
Takeda	Zasocitinib	—	RECRUITING	2029-12-18	NCT07286058
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	Picankibart	—	RECRUITING	2029-12-31	NCT07295509
Bristol-Myers Squibb	Deucravacitinib	Tyrosine Kinase 2 Inhibitor [EPC]	RECRUITING	2030-03-06	NCT06869551
Amgen	Apremilast	Phosphodiesterase 4 Inhibitor [EPC]	RECRUITING	2036-03-17	NCT05767047
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-1314 injection	—	RECRUITING	2026-04-30	NCT06640257
UCB Biopharma SRL	bimekizumab	—	ACTIVE NOT RECRUITING	2027-03-09	NCT06506916
Sun Pharmaceutical Industries Limited	TILD sub-cutaneous (SC) injection	—	ACTIVE NOT RECRUITING	2028-12	NCT04991116
UCB Biopharma SRL	Bimekizumab	—	ACTIVE NOT RECRUITING	2026-02-06	NCT06624228
Sun Pharmaceutical Industries Limited	TILD	—	ACTIVE NOT RECRUITING	2025-06-04	NCT04314531
Bristol-Myers Squibb	Deucravacitinib	Tyrosine Kinase 2 Inhibitor [EPC]	ACTIVE NOT RECRUITING	2024-09-05	NCT04908202
Eli Lilly	Ixekizumab	Interleukin-17A Antagonist [EPC]	ACTIVE NOT RECRUITING	2024-02-19	NCT04527380
Bristol-Myers Squibb	Deucravacitinib	Tyrosine Kinase 2 Inhibitor [EPC]	ACTIVE NOT RECRUITING	2024-02-06	NCT04908189
AbbVie	Risankizumab	—	ACTIVE NOT RECRUITING	2020-10-08	NCT03675308
AbbVie	Risankizumab	—	ACTIVE NOT RECRUITING	2020-06-22	NCT03671148
UCB Biopharma SRL	Bimekizumab	—	COMPLETED	2026-05-26	NCT04009499
Eli Lilly	Ixekizumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2025-11-18	NCT06588296
Sun Pharmaceutical Industries Limited	TILD	—	COMPLETED	2025-03-26	NCT04314544
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2024-11-07	NCT03769168
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2024-10-22	NCT04632927
Bio-Thera Solutions	BAT2506	—	COMPLETED	2023-10-06	NCT05046431
Sun Pharmaceutical Industries Limited	SUNPG18_07 I (Tildrakizumab 200 mg)	—	COMPLETED	2023-09-18	NCT03552276
Novartis	AIN457	—	COMPLETED	2022-06-02	NCT04711902
Novartis	AIN457 6 mg/kg i.v.	—	COMPLETED	2022-05-17	NCT04209205
UCB Biopharma SRL	Bimekizumab	—	COMPLETED	2021-12-08	NCT03896581
UCB Biopharma SRL	Bimekizumab	—	COMPLETED	2021-08-17	NCT03895203
Pfizer	Tofacitinib	—	COMPLETED	2021-04-28	NCT03486457
Novartis	AIN457 (secukinumab)	—	COMPLETED	2020-11-10	NCT02662985
UCB Biopharma SRL	Bimekizumab	—	COMPLETED	2020-11-05	NCT04109976
Novartis	secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2020-10-07	NCT03031782
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2019-12-30	NCT02745080
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2019-12-11	NCT02771210
AbbVie	Adalimumab	TNF	COMPLETED	2019-09-26	NCT03104400
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2019-07-23	NCT03104374
Biocad	BCD-085	—	COMPLETED	2019-06-26	NCT03598751
UCB Biopharma SRL	Bimekizumab	—	COMPLETED	2019-01-08	NCT03370133
UCB Biopharma SRL	Bimekizumab	—	COMPLETED	2018-12-28	NCT03410992
Eli Lilly	Ixekizumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2018-10-30	NCT02584855
UCB Biopharma S.P.R.L.	e-Device	—	COMPLETED	2018-07-02	NCT03357471
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2018-01-11	NCT01892436
Amgen	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2018-01-09	NCT02376790
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2017-08-16	NCT02404350
Eli Lilly	Ixekizumab 80 mg Q4W	—	COMPLETED	2016-09-09	NCT02349295
Pfizer	Tofacitinib	—	COMPLETED	2016-04	NCT01882439
Pfizer	Tofacitinib 5 mg BID	—	COMPLETED	2015-12-18	NCT01877668
Bausch Health Americas, Inc.	210 mg brodalumab	—	COMPLETED	2015-10	NCT02024646
Bristol-Myers Squibb	Abatacept	Selective T Cell Costimulation Modulator [EPC]	COMPLETED	2015-07-14	NCT01860976
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2015-05-27	NCT01989468
Tanabe Pharma Corporation	TA-650	—	COMPLETED	2015-03	NCT01680159
Amgen	Apremilast 30 mg	—	COMPLETED	2015-02-25	NCT01925768
Kyowa Kirin Co., Ltd.	KHK4827 140mg SC	—	COMPLETED	2015-01-28	NCT02052609
Novartis	Secukinumab (75 mg)	—	COMPLETED	2014-10	NCT01392326
Amgen	Apremilast	Phosphodiesterase 4 Inhibitor [EPC]	COMPLETED	2014-07-03	NCT01690299
Novartis	Secukinumab (AIN457)	—	COMPLETED	2014-05-12	NCT01752634
Amgen	Etanercept / Autoinjector A	—	COMPLETED	2013-12-18	NCT01901185
Amgen	Apremilast 20mg	—	COMPLETED	2013-02-21	NCT01307423
Amgen	Apremilast 20mg	—	COMPLETED	2012-08-21	NCT01212770
Amgen	Apremilast 20mg	—	COMPLETED	2012-07-26	NCT01212757
Amgen	Apremilast 20mg	—	COMPLETED	2012-04-27	NCT01172938
ACELYRIN Inc.	Izokibep	—	TERMINATED	2023-11-30	NCT05623345
Gilead	Filgotinib	—	TERMINATED	2021-01-19	NCT04115748
Gilead	Filgotinib	—	TERMINATED	2021-01-04	NCT04115839
Bausch Health Americas, Inc.	210 mg brodalumab	—	TERMINATED	2015-10	NCT02029495

Showing 29 of 29 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Merck	Tulisokibart	—	RECRUITING	2027-08-13	NCT07486960
InventisBio Co., Ltd	D-2570	—	RECRUITING	2027-08-15	NCT07315061
AbbVie	Lutikizumab	—	RECRUITING	2027-12	NCT06865105
Hansoh BioMedical R&D Company	HS-10374	—	RECRUITING	2026-04-28	NCT06176508
Spyre Therapeutics, Inc.	SPY002-072	—	ACTIVE NOT RECRUITING	2026-10-31	NCT07148414
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQH3906 Capsule	—	NOT YET RECRUITING	2027-08	NCT07406035
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-1314 injection	—	COMPLETED	2024-06-05	NCT05055934
Takeda	NDI-034858	—	COMPLETED	2023-05-04	NCT05153148
ACELYRIN Inc.	ABY-035	—	COMPLETED	2021-10-01	NCT04713072
UCB Biopharma SRL	Bimekizumab	—	COMPLETED	2020-10-29	NCT03347110
Galapagos NV	Filgotinib	—	COMPLETED	2020-08-14	NCT03926195
Bristol-Myers Squibb	BMS-986165 Dose A	—	COMPLETED	2020-04-27	NCT03881059
Pfizer	PF-06700841	—	COMPLETED	2020-04-06	NCT03963401
Sun Pharmaceutical Industries Limited	SUNPG1623 I	—	COMPLETED	2019-03-01	NCT02980692
AbbVie	risankizumab	—	COMPLETED	2018-07-08	NCT02986373
Galapagos NV	filgotinib	—	COMPLETED	2018-03-12	NCT03101670
UCB Biopharma S.P.R.L.	Bimekizumab	—	COMPLETED	2017-11	NCT02969525
AbbVie	adalimumab	TNF	COMPLETED	2016-07-04	NCT02349451
Johnson & Johnson	Guselkumab	Interleukin-23 Antagonist [EPC]	COMPLETED	2016-05-31	NCT02319759
AbGenomics B.V Taiwan Branch	AbGn-168H	—	COMPLETED	2015-10	NCT02267642
Amgen	Apremilast	Phosphodiesterase 4 Inhibitor [EPC]	COMPLETED	2014-11-20	NCT01988103
Novartis	AIN457A	—	COMPLETED	2012-11	NCT01169844
Inflexxion, Inc.	—	—	COMPLETED	2012-11	NCT01463189
Novartis	AIN457	—	COMPLETED	2010-12	NCT00809614
Ventyx Biosciences, Inc	Dose A VTX958	—	TERMINATED	2024-01-02	NCT05715125
Aclaris Therapeutics, Inc.	ATI-450	—	TERMINATED	2023-12-06	NCT05511519
Galapagos NV	filgotinib	—	TERMINATED	2021-06-30	NCT03320876
AbbVie	ABT-122	—	TERMINATED	2016-05	NCT02429895
Bausch Health Americas, Inc.	AMG 827 140	—	TERMINATED	2012-09	NCT01516957

Showing 15 of 15 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
UCB Biopharma SRL	Bimekizumab	—	RECRUITING	2027-05-03	NCT06888193
Seismic Therapeutic AU Pty Ltd	S-4321	—	RECRUITING	2027-09	NCT07455578
UCB Biopharma SRL	Bimekizumab regimen 1 iv	—	RECRUITING	2028-05-18	NCT07290036
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	RECRUITING	2032-11-30	NCT06751238
LAPIX Therapeutics Inc.	LPX-TI641	—	RECRUITING	2025-12-15	NCT06628206
selectION Therapeutics GmbH	si-544	—	COMPLETED	2025-06-23	NCT06191042
Johnson & Johnson	Ustekinumab	Interleukin-12 Antagonist [EPC]	COMPLETED	2024-01-26	NCT05252533
Bio-Thera Solutions	BAT2506 injection	—	COMPLETED	2023-06-27	NCT05332730
UCB Biopharma SRL	Pharmacokinetics of certolizumab pegol	—	COMPLETED	2023-05-23	NCT04163016
Bio-Thera Solutions	Drug: BAT2506 injection Other Names: Simponi(EU-licensed)	—	COMPLETED	2020-12-31	NCT04152759
Fresenius Kabi SwissBioSim GmbH	40 mg MSB11022	—	COMPLETED	2020-03-17	NCT04018599
Bristol-Myers Squibb	Methotrexate	Folate Analog Metabolic Inhibitor [EPC]	COMPLETED	2018-03-20	NCT03402087
UCB BIOSCIENCES, Inc.	Certolizumab Pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2016-10	NCT02019602
UCB BIOSCIENCES, Inc.	Certolizumab Pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2015-12	NCT02154425
UCB Celltech	UCB4940 40 mg	—	COMPLETED	2015-08	NCT02141763

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Psoriatic Arthritis

TNF-alpha (20)

Novel Psoriatic Arthritis Drugs by Company (New molecular entities)

5 companies have an FDA-approved novel drug for Psoriatic Arthritis.

Johnson & Johnson 4 drugs

UCB INC 2 drugs

QUESTCOR PHARMA 1 drug

H.P. ACTHAR GEL

REPOSITORY CORTICOTROPIN

IMMUNEX 1 drug

AbbVie 1 drug

Reformulations (6 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Psoriatic Arthritis Drug Targets

Molecular targets of approved and investigational Psoriatic Arthritis drugs — 14 targets tracked.

TNF 20 IL-12 7 IL-23 7 JAK1 3 JAK2 3 ACTH 1 Melanocortin receptors 1 IL17A 1 IL-17AF 1 IL-17F 1 TNF-beta 1 JAK3 1 TYK2 1 PDE4 1

Biosimilars (20 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

Generic Drugs (3 ANDA approved) Click to expand

Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).

Related Indications

Other Immunology indications

View all Immunology

Drug Categories:

Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
Biosimilars: BLA-approved biologics highly similar to reference products
Generics: ANDA-approved copies of small molecule drugs

View data sources and methodology